Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the efficacy and safety of the combination of capecitabine + bevacizumab concomitantly with radiotherapy versus capecitabine concomitantly with radiotherapy, as neoadjuvant treatment for patients with localized and resectable rectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum

NCT00909987

Rectum Cancer

COMPLETED PHASE2

Xeloda and Bevacizumab to Treat Rectal Cancer

NCT00847119

Rectal Cancer

COMPLETED PHASE2

Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer

NCT00828672

Locally Advanced Rectal Cancer

COMPLETED PHASE2

Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy

NCT00671645

Rectal Cancer

TERMINATED PHASE2

Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study

NCT00842686

Locally Advanced Rectal Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Bevacizumab + Capecitabine + Radiotherapy

Group Type EXPERIMENTAL

Bevacizumab + Capecitabine + Radiotherapy

Intervention Type DRUG

Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)

B

Capecitabine + Radiotherapy

Group Type ACTIVE_COMPARATOR

Capecitabine + Radiotherapy

Intervention Type DRUG

Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bevacizumab + Capecitabine + Radiotherapy

Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)

Intervention Type DRUG

Capecitabine + Radiotherapy

Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Age ≥18 years
* ECOG ≤ 1
* Histologically confirmed carcinoma of the rectum
* Localized and resectable rectal cancer
* No metastatic disease
* Measurable disease
* Life expectancy more than 4 months
* Non prior treatment for rectal cancer
* Adequate haematological function: leu ≥ 4x 109 /l, Hb ≥10 gr/dl, neutropils≥ 1,5 x 109 /l and platelets ≥100 x 109 /l
* Adequate renal function: creatinine ≤ 106 umol/l or calculated creatinine clearance \> 50 mL/min
* Adequate liver function: AST, ALT and alkaline phosphatase ≤2.5 x UL, bilirubin ≤1.5 x UL
* Adequate nutritional weight loss \<10% of regular weight and albumin ≥ 35 g/l

Exclusion Criteria

* Unresectable rectal cancer
* Past or current history (within the last 5 years prior to treatment start) of other malignancies.
* Patients of childbearing potential not willing to use effective means of contraception.
* Clinically significant cardiovascular disease
* Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take oral medication.
* Patients subjected to organ allografts who require immunosuppressive treatment.
* Severe, non-cicatrized osseous fractures, wounds or ulcers.
* Indications of hemorrhagic diathesis or coagulopathy.
* Severe, uncontrolled intercurrent infections or other severe, uncontrolled concomitant diseases.
* History of unexpected severe reactions to treatment with fluoropyrimidines or known deficiency dihydropyrimidine dehydrogenase deficiency (DPD).
* Patients subjected to a major surgical procedure, open biopsy or who have had significant traumatic lesions within the 28 days prior to beginning the treatment of the study or in whom it is foreseen that a major surgical procedure will be necessary during the course of the study; fine-needle aspiration within the 7 days prior to beginning the treatment of the study.
* Current or recent use (within the 10 days prior to beginning the treatment of the study) of oral or parenteral anticoagulants at complete doses or thrombolytic agents. The use of low doses of warfarin is allowed, with an International Normalized Ratio \[INR\] of \< 1.5.
* Daily chronic treatment with high doses of aspirin (\> 325 mg/day) or non-steroid anti-inflammatory medications (which inhibit the platelet function at doses used for treating chronic inflammatory diseases).
* Patients who have received any drug or agent/procedure under research, i.e., who have participated in another clinical trial during the 4 weeks prior to beginning the treatment with the medications of the study
* Any psychological, familiar conditions suggesting that the patient will not be able to complete the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No